DataPulse at ENDO 2026: Rewriting the Calcium Code in ADH1

Rare disease management may be entering a pivotal new chapter. Join leading experts from ENDO 2026 as they unpack the phase 3 CALIBRATE findings, answer pressing clinical questions, and explore how emerging mechanism-based approaches could reshape the diagnosis, monitoring, and treatment of autosomal dominant hypocalcemia type 1 (ADH1). Across this three-part series, gain practical insights into the data, the science behind targeted therapy, and the evolving future of care for patients with ADH1.